These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 29909548)

  • 1. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
    Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
    Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
    Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
    Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
    Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
    Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations.
    Nambirajan A; Sharma A; Rajeshwari M; Boorgula MT; Doddamani R; Garg A; Suri V; Sarkar C; Sharma MC
    Brain Tumor Pathol; 2021 Jan; 38(1):30-40. PubMed ID: 33130928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity within the PF-EPN-B ependymoma subgroup.
    Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
    Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.
    Han J; Yu M; Bai Y; Yu J; Jin F; Li C; Zeng R; Peng J; Li A; Song X; Li H; Wu D; Li L
    Cancer Cell; 2020 Dec; 38(6):844-856.e7. PubMed ID: 33186520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.
    Jain SU; Do TJ; Lund PJ; Rashoff AQ; Diehl KL; Cieslik M; Bajic A; Juretic N; Deshmukh S; Venneti S; Muir TW; Garcia BA; Jabado N; Lewis PW
    Nat Commun; 2019 May; 10(1):2146. PubMed ID: 31086175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2.
    Jain SU; Rashoff AQ; Krabbenhoft SD; Hoelper D; Do TJ; Gibson TJ; Lundgren SM; Bondra ER; Deshmukh S; Harutyunyan AS; Juretic N; Jabado N; Harrison MM; Lewis PW
    Mol Cell; 2020 Nov; 80(4):726-735.e7. PubMed ID: 33049227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
    Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
    Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3 K27M mutations are extremely rare in posterior fossa group A ependymoma.
    Ryall S; Guzman M; Elbabaa SK; Luu B; Mack SC; Zapotocky M; Taylor MD; Hawkins C; Ramaswamy V
    Childs Nerv Syst; 2017 Jul; 33(7):1047-1051. PubMed ID: 28623522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
    Jenseit A; Camgöz A; Pfister SM; Kool M
    Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
    Łastowska M; Matyja E; Sobocińska A; Wojtaś B; Niemira M; Szałkowska A; Krętowski A; Karkucińska-Więckowska A; Kaleta M; Ejmont M; Tarasińska M; Perek-Polnik M; Dembowska-Bagińska B; Pronicki M; Grajkowska W; Trubicka J
    J Pathol Clin Res; 2021 Nov; 7(6):565-576. PubMed ID: 34314101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.
    Michealraj KA; Kumar SA; Kim LJY; Cavalli FMG; Przelicki D; Wojcik JB; Delaidelli A; Bajic A; Saulnier O; MacLeod G; Vellanki RN; Vladoiu MC; Guilhamon P; Ong W; Lee JJY; Jiang Y; Holgado BL; Rasnitsyn A; Malik AA; Tsai R; Richman CM; Juraschka K; Haapasalo J; Wang EY; De Antonellis P; Suzuki H; Farooq H; Balin P; Kharas K; Van Ommeren R; Sirbu O; Rastan A; Krumholtz SL; Ly M; Ahmadi M; Deblois G; Srikanthan D; Luu B; Loukides J; Wu X; Garzia L; Ramaswamy V; Kanshin E; Sánchez-Osuna M; El-Hamamy I; Coutinho FJ; Prinos P; Singh S; Donovan LK; Daniels C; Schramek D; Tyers M; Weiss S; Stein LD; Lupien M; Wouters BG; Garcia BA; Arrowsmith CH; Sorensen PH; Angers S; Jabado N; Dirks PB; Mack SC; Agnihotri S; Rich JN; Taylor MD
    Cell; 2020 Jun; 181(6):1329-1345.e24. PubMed ID: 32445698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anatomic Neuroimaging Characteristics of Posterior Fossa Type A Ependymoma Subgroups.
    Sabin ND; Hwang SN; Klimo P; Chambwe N; Tatevossian RG; Patni T; Li Y; Boop FA; Anderson E; Gajjar A; Merchant TE; Ellison DW
    AJNR Am J Neuroradiol; 2021 Dec; 42(12):2245-2250. PubMed ID: 34674998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of H3 K27M mutations in posterior fossa ependymomas.
    Gessi M; Capper D; Sahm F; Huang K; von Deimling A; Tippelt S; Fleischhack G; Scherbaum D; Alfer J; Juhnke BO; von Hoff K; Rutkowski S; Warmuth-Metz M; Chavez L; Pfister SM; Pietsch T; Jones DT; Sturm D
    Acta Neuropathol; 2016 Oct; 132(4):635-7. PubMed ID: 27539613
    [No Abstract]   [Full Text] [Related]  

  • 17. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
    Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K;
    Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome.
    Jünger ST; Andreiuolo F; Mynarek M; Dörner E; Zur Mühlen A; Rutkowski S; von Bueren AO; Pietsch T
    Childs Nerv Syst; 2020 Nov; 36(11):2693-2700. PubMed ID: 32474813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
    Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
    PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent pediatric infratentorial ependymomas: a systematic review and meta-analysis on outcomes and molecular classification.
    Montgomery EY; Thirunavu V; Pagadala M; Shlobin NA; Plant-Fox AS; Lam S; DeCuypere M
    J Neurosurg Pediatr; 2023 Feb; 31(2):132-142. PubMed ID: 36433871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.